Showing results (471-480 of 884) with videos related to
Sort By:
Pageof 89
Digestive Diseases and Sciences|June 10, 2021
Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel DiseasesNghia H Nguyen, Xian Zhang, Millie D Long, et al.Waste Management (New York, N.Y.)|February 6, 2023
Investigation of agro-forestry and construction demolition wastes in alkali-activated fly ash bricks as sustainable building materialsSiddharth Singh, Mickey Mecon Dalbehera, Soumitra Maiti, et al.ADMET & DMPK|December 1, 2025
Epithelial-mesenchymal dynamics in cancer: Role of signalling pathways, stromal interactions and natural therapiesIram Khan, Anindita Behera, Kamesh R Babu, et al.The American Journal of Gastroenterology|October 24, 2003
Management of Crohn's disease of the ileoanal pouch with infliximabJean-Frederic Colombel, Elena Ricart, Edward V Loftus, et al.Crohn'S & Colitis 360|February 3, 2025
Certolizumab Pegol Treatment in Patients With Crohn's Disease: Final Safety Data From the SECURE RegistryGary R Lichtenstein, Scott D Lee, Brian G Feagan, et al.The American Journal of Gastroenterology|June 6, 2018
Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid RegistryGeert DʼHaens, Walter Reinisch, Remo Panaccione, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 19, 2014
A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitisSiddhant Yadav, Maneesh Dave, Jithinraj Edakkanambeth Varayil, et al.Abdominal Imaging|June 14, 2008
CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findingsFargol Booya, Salma Akram, Joel G Fletcher, et al.Melanoma Research|May 2, 2015
Ipilimumab-induced colitis in patients with metastatic melanomaKara M De Felice, Arjun Gupta, Sagar Rakshit, et al.Journal of Crohn'S & Colitis|October 11, 2022
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction StudiesPaul Bahnam, Jurij Hanzel, Christopher Ma, et al.Pageof 89